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Abstract  
Background: The use of combination antiretroviral therapy (cART) has substantially improved the outlook for 
patients with HIV infection. However, lifelong exposure to cART is also associated with adverse metabolic 
changes and an enhanced risk of renal, hepatic and cardiovascular dysfunction. This study investigated 
disruptions of the urinary metabolome of cART-exposed patients, thereby furthering our understanding of 
some of the side effects of pharmaceutical intervention. 
Methods: HIV-positive patients were recruited from an HIV clinic and divided into cART-naïve and cART-
exposed groups. HIV-negative patients were recruited from a sexual health clinic. All 89 subjects were white 
males. Targeted biochemistry analyses were performed on plasma samples. Urine samples were collected 
following an overnight fast and analysed with a highly sensitive untargeted metabolomic method using 
nanoflow/nanospray liquid chromatography-time of flight mass spectrometry. Datasets were analysed using 
projection modelling to detect metabolite markers of cART exposure.  
Results: Metabolites or parent compounds of all cART drugs were detected in urine extracts of all but one of 
the cART-exposed patients confirming adherence to the pharmaceutical regimen.  Analysis of urine samples 
from patients on cART revealed significant reductions in selected bile acids, lipid, nucleoside and androgen 
metabolites. However, plasma concentrations of free or conjugated testosterone were unchanged indicating 
possible disruption of androgen transport or excretion in urine of patients on cART. 
Conclusions: Discovery-based metabolomics reveals the potential to identify novel markers of cART 
intervention and metabolite disruption in HIV-positive patients, which may enable the efficacy, compliance 
and side effects of these pharmaceutical mixtures to be investigated.  
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Introduction 
The introduction of combination antiretroviral therapy (cART) has transformed HIV infection from a 
life-threatening disease into a chronic condition. Multiple co-morbidities not associated with AIDS, such as 
cardiovascular, renal, bone and hepatic diseases, are becoming more prevalent in HIV-positive individuals 
compared to those without the infection.1 Although the ageing process and the virus itself might play an 
important role in the development of non-AIDS comorbidities, the cumulative effects of cART have been 
associated with the onset and progression of non-AIDS co-morbidities in HIV infection. For instance, 
nucleotide reverse transcriptase inhibitors (NRTIs), such as tenofovir disoproxil fumarate (TDF), have been 
linked with proximal tubular renal disease and reduced bone mineral density2,3, while abacavir has been 
found to increase the risk of ischaemic heart disease in cohort studies.4  Protease inhibitors (PIs), another 
class of antiretrovirals frequently used in clinical practice have been widely associated with complications, 
such as dyslipidemia, abnormal fat distribution, and insulin resistance.5-7 
Currently, it is not possible to predict which patients are more likely to develop a particular non-AIDS 
comorbidity after starting cART. Therefore, there is an urgent need for biomarkers that can predict and guide 
therapy in people living with HIV affected by non-AIDS comorbidities. The use of a discovery-based 
untargeted metabolomics approach may help to further elucidate mechanisms of action, metabolism and 
toxicity associated with the use of cART.8 This analytical approach allows the profiling of a wide range of 
metabolites in a patient’s biofluids, such as urine and blood, and therefore has great potential for the 
discovery of biomarkers of pharmaceutical efficacy and toxicity in HIV infection. To date, the effect of cART 
exposure on urinary metabolite profiles has not been studied using trace analytical methods, yet analysis of 
this biofluid may provide a useful non-invasive screen for pharmaceutical efficacy and toxic side effects 
arising from exposure to combinations of NRTIs and PIs.  
This study aims to investigate the effect of two cART regimens on the urinary metabolome in 
comparison with cART-naïve HIV-positive and negative patients. Urine samples were extracted and analysed 
using, for the first time, highly sensitive nanoflow liquid chromatography-nanoelectrospray–mass 
spectrometry methods, which enable sensitive non-targeted analysis of urine samples to detect disruption 
in metabolite profiles associated with cART intervention.  
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Methods 
Study population 
Fasted urine and plasma samples were collected between 2010 and 2011 from HIV-positive patients 
participating in a longitudinal study investigating reduced bone mineral density in HIV-positive men from a 
single HIV outpatient clinic in Brighton, UK.9  HIV-negative men were recruited from a single sexual health 
clinic in Brighton. All subjects were white males and exclusion criteria were men (HIV-infected and HIV-
negative) <18 years old,  patients unable to give written, informed consent, patients who have had imaging 
with contrast in the previous 48 hours, or are infected with hepatitis C virus, showing moderate to severe 
hepatotoxicity, renal insufficiency or reduced bone mineral density at the time of sampling.  Participants 
were classified into 3 study groups: HIV-positive on cART; HIV-positive cART-naïve and HIV-negative. For all 
study groups, demographic and HIV parameters, including age, ethnicity, current and nadir CD4 cell count, 
current HIV viral load, time since HIV diagnosis and time since initiating cART were obtained from the main 
study clinic database. Ethical approval was given by the NHS Research Ethics Committee (NREC 
09/H1107/101) and all patients gave written, informed consent.  
cART regimens and urine sample collection 
HIV-positive patients on cART were on a combination of TDF, emtricitabine and the PI booster 
ritonavir.  Additionally, they were also on either the PI atazanavir or darunavir, which was the only way in 
which the cART regimens differed. The characteristics and structures of the pharmaceuticals used in cART 
are given in Supplementary Table S1 and Figure S1.  
Urine osmolality was measured using a Model 3320 osmometer (Advanced Instruments Inc., Massachusetts, 
U.S.A) and an aliquot of the remaining sample was frozen at -80 °C in 10% methanol prior to sample extraction 
for metabolomics analyses.  
Targeted plasma and urine biochemistry 
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All blood plasma and urine chemistries were performed on a Cobas Integra 800 analyser (Roche 
Diagnostics, UK). Urine total protein concentration was measured by turbidimetry after alkaline denaturation 
and precipitation with benzethonium chloride, with a measuring range of 40–2000 mg/L. Imprecision 
(analytical error)  was 3.9% at 55 mg/L and 2.5% at 260 mg/L. Urine albumin was measured by 
immunoturbimetric assay using polyclonal sheep anti-human albumin antisera with a working analytical 
range of 12–200 mg/L. Imprecision was 2.0% at 20 mg/L and 2.3% at 120 mg/L. Samples with a concentration 
above these upper limits were automatically re-run at dilution. Urine creatinine concentration was 
determined by enzymatic (creatininase) colorimetry with a measuring range of 0.1–40.0 mmol/L and 
imprecision was 1.8% at 5.8 mmol/L and 3.6% at 25.6 mmol/L. 
Metabolomics analyses of urine samples 
Full details of urine extraction methods and their analyses are given in the supplementary 
information. Briefly, urine was extracted as previously described by our laboratory 10 and extracts were 
reconstituted to give a final osmolality of 1360 mOsm prior to MS analysis.11  Quality control (QC samples) 
and sample extracts were analysed by nanoflow ultrahigh performance liquid chromatography-nano 
electrospray ionisation time of flight mass spectrometer (nUHPLC-nESI-TOFMS) as described in recent 
studies.12 This analytical methodology allows the profiling of a wide range of  small molecule metabolites 
present in urine samples, including steroids, lipids, neurotransmitters, peptides and nucleotides.10 MS 
datasets were processed and analysed by multivariate modelling, including principal components analyses 
(PCA) and orthogonal partial least squares-discriminant analysis (OPLS-DA), to identify metabolite differences 
between treatment groups. Discriminating metabolites of cART intervention were detected using S-plots 
from OPLS-DA models which were constructed for atazanavir versus cART-naïve patients and for darunavir 
versus cART-naïve patients. Following the exclusion of ions associated with the parent cART drugs and their 
metabolites, further OPLS-DA models and S-plots were constructed between the cART-naïve and cART groups 
to identify endogenously derived metabolites that were markers of cART treatment. Metabolite identities 
were determined from their accurate mass, isotopic fit and comparison of fragmentation data with authentic 
standards or metabolite databases.  
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Statistical analyses 
Univariate statistical analysis of urinary marker metabolites (and targeted blood biochemistry) was 
performed using SPSS version 22 (IBM, New York, USA). Metabolites were tested for normality and for 
significance at p<0.05 using a one-way ANOVA with a Games-Howell test (because of unequal variances) to 
determine p-values. Non-normally distributed data were log10 transformed prior to ANOVA.  A false discovery 
rate of 5% was used to check for the occurrence of type 1 errors arising from multiple testing. 13  Linear 
regression modelling was used to adjust for the confounding effects of age and urine protein/creatinine ratio 
(uPCR) (see results in Table 1) on the association of metabolite disruptions in the different patient groups . 
Results  
Patient data and targeted blood biochemistry 
In total, samples from 89 patients were analysed, comprising 13 cART-naïve HIV-negative patients, 
26 cART-naïve HIV-positive patients and 50 HIV-positive patients on cART. Of these 50 patients, 20 were on 
atazanavir and 30 were on darunavir. All patients, except one, were on the specified cART regimen for at 
least a month prior to sampling: those on atazanavir for a (mean (SD)) period of 16.8 (11.0) months and 
darunavir for 12.9 (7.0) months. 
Clinical data for patient groups are summarised in Table 1. All subjects were white males between 
the ages of 20-71. All HIV-positive patients on cART had a plasma HIV viral load <40 RNA copies/ml in contrast 
to the high and variable viral load in the cART-naïve HIV-positive group (Table 1). Nadir CD4 counts were 
lower in those on cART, but at the time of urine sampling there was no difference in CD4 cell counts measured 
between those on cART and those that were cART-naïve. There were also no clear indications of major kidney 
or liver toxicity for those on atazanavir or darunavir. However, the uPCR, a marker of kidney injury, was 
significantly increased in those on cART compared to the HIV-negative patients, but values in all study groups 
were within the reference range. The urine albumin creatinine ratio (uACR), another marker of kidney 
disease, was unchanged in those on cART. Bilirubin and alkaline phosphatase (ALP) levels were, as expected, 
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increased in the atazanavir group compared with the cART-naïve and darunavir groups; this is a common side 
effect of atazanavir medication due to disrupted biliary excretion.14 
Plasma triglyceride and cholesterol levels were significantly increased in the darunavir group 
compared to the cART-naïve and HIV-negative groups, respectively. There was no significant variation in free 
or total testosterone levels in plasma, however, steroid hormone binding globulin (SHBG) levels were 
significantly higher in patients on cART compared to the HIV-negative group.  
Metabolomic analysis of the effect of cART treatment 
Analyses of the QC samples revealed highly repeatable data indicating acceptable extraction and MS 
instrumental performance (see Supplementary  Results). The urinary metabolomic profiles of individuals 
taking the two cART regimens were compared to cART-naïve HIV-positive and HIV-negative groups using PCA 
modelling. The data sets comprised 6705 and  9043 MS features in positive and negative mode respectively. 
The grouping of patient samples on plots of both scores of data obtained in + and – nESI modes were similar 
and revealed no discrimination between the metabolomic profiles of urine from cART-naïve and HIV-negative 
patients (Figure 1 and Supplementary Figure S2). Patients on cART regimens containing either atazanavir or 
darunavir clustered separately and away from the cART-naïve group. In +nESI, the two cART treatment groups 
were separated from the cART-naïve group on the first component and from each other on the second 
component, whereas in -nESI discrimination was only observed on the first component.  
Identification of cART drugs and metabolites 
Discriminating metabolites of cART intervention were detected using S-plots from OPLS-DA models 
(see Figure 2 and Supplementary Figure S3 for examples). The majority of the discrimination between the 
cART-naïve and exposed groups was driven by ions associated with the cART drugs and their metabolites. A 
total of 16 structures were identified, four of which were the parent drug compounds, and the remaining 
were metabolites of three PIs (Tables 2 and Supplementary Table S2). Identification of the metabolites was 
supported by fragmentation patterns which were compared to those of metabolite structures that had 
already been detected in rodent urine, human blood and hepatocyte studies. 15-18 Analysis of the OPLS-DA 
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loadings plot for each cART parent compound confirmed that all but one urine sample contained cART drugs 
at the time of sample donation. As none of the parent drugs nor any of their metabolites were detected in 
urine extracts from this patient in the darunavir group, this sample was excluded from further statistical 
analyses. 
Effect of cART intervention on the endogenously derived metabolome 
Following the exclusion of ions associated with the parent cART drugs and their metabolites, further 
OPLS-DA models were constructed to identify endogenously derived metabolites that were associated with 
cART treatment. Interrogation of the S-plots uncovered 13 endogenous metabolites that discriminated 
between the sample groups after accounting for a false discovery rate of 5%. These included 5 bile 
acids/alcohols, 4 conjugated androgens, and a nucleoside, lipid, peptide and unidentified metabolite. Details 
of the determination of metabolite identity following fragmentation of the molecular ion are given in 
Supplementary Table S3. The effect of age and uPCR as potential confounding variables influencing the 
association of the urinary metabolites with cART status was analysed using linear regression modelling. After 
adjusting for confounders, the analysis revealed that 12 metabolites were significantly decreased in urine of 
cART exposed groups patients compared to either the cART-naïve and/or HIV-negative groups. One 
metabolite, a tetra-peptide, was significantly increased in urine from in the atazanavir cART group compared 
with the cART-naïve group (Table 3).   
 
Discussion 
Metabolism of cART drugs 
An advantage of using a global metabolomics analysis of urine samples is that both exogenously-
derived compounds, such as administered drugs and other xenobiotics, are detected as well as changes in 
endogenously-derived biochemical metabolites. In this study, the parent compounds of all three PIs and two 
NRTI drugs were detected in urine samples from cART-exposed groups. The PIs were also highly metabolised 
by each patient, whereas only the parent NRTIs, tenofovir or emtricitabine, were detected in urine extracts 
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in keeping with previous studies indicating that these compounds are poorly metabolised in the humans. 19,20 
In agreement with previous in vitro studies two metabolites of ritonavir were detected in urine extracts (the 
oxidised and deacylated products), however the glutathione conjugate was not detected and this metabolite 
may have preferentially been excreted by the biliary route.15 The detection of a number of metabolites of 
atazanavir and darunavir in this study agreed with previous work showing that these pharmaceuticals are 
extensively metabolised in humans via oxidation, carbamate hydrolysis, deacylation (atazanavir) and 
glucuronidation (darunavir).16,17  
The ability to detect the parent cART drugs and a wide range of their transformation products in 
urine extracts suggest that in future studies, links between pharmacogenetics, metabolism and drug efficacy 
could be investigated, which may lead to a more personalised approach to cART intervention. In addition, it 
is also possible to identify individuals who have not taken the medication, which was evident for one patient 
in our study from the darunavir group where neither darunavir nor any of its metabolites or any other cART 
drugs were detected in their urine sample.   
Variation in the endogenous metabolome as a result of cART 
The PCA scores plot (Figure 1 and Supplementary Figure S2), as well as further modelling studies 
using OPLS-DA, did not reveal any discrimination between the cART-naïve and HIV-negative groups despite 
their different HIV statuses. Furthermore, stratification of the cART-naïve group by nadir or current CD4 count 
into two groups (≤250 and ≥250 cells/µL) did not result in discrimination between these sample groups. A 
possible explanation is that metabolomic changes associated with immunosuppression may not be detected 
in urine samples from HIV-positive patients. Instead, analyses of blood samples may elucidate early stage 
metabolomic consequences of HIV infection. Other studies analysing blood samples from cART-naïve HIV 
patients report disrupted lipid and carbohydrate metabolism and changes in organic acids associated with 
oxidative stress and disturbed mitochondrial metabolism. 8,21 
In the current study, 12 metabolites were detected which decreased in the urine of HIV-positive 
patients on cART. Of these, four were bile acids which, depending on the metabolite and after adjusting for 
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confounding variables, were detected at between 2 and 80 times lower levels in the urine from both cART 
groups (Table 3). In contrast, previous studies have detected increased levels of plasma bile acids in patients 
receiving cART or PIs.22,23 Plasma concentrations of bile acids were not measured in our study but blood ALT 
levels did not suggest significant liver damage. However, plasma/hepatocyte  concentrations of bile acids are 
also influenced by cell membrane transporters such as organic anion transporting polypeptides (OATPs) and 
two subtypes, OATP2B1 and OATP1B1, are inhibited by PIs including atazanavir, darunavir and ritonavir.24-26 
In addition, apical membrane transporters such as ATP-binding cassette transporter B11 (ABCB11) which 
export bile acids from the hepatocytes into the bile are also inhibited by PIs.27-29 These transporters are also 
present in the apical membrane of proximal tubules of the kidney.30,31 Thus, they may be involved in the 
excretion of bile acids into the urine, and if inhibited by PIs, this may result in decreased levels of urinary bile 
acids. However, in the current study only a subset of the total bile acids that were present in the urine extracts 
were disrupted (Supplementary Table S4), implying that these transporters may have different affinities for 
the various bile acids.  
The results show lower concentrations of a bile alcohol, cholestanehexol glucuronide, in the urine of 
patients on cART. Bile alcohols are end products of cholesterol metabolism and are minor components in the 
bile and urine of healthy subjects. However, increased concentrations of conjugated bile alcohols have been 
detected in patients with primary biliary cirrhosis, an autoimmune disease.32 Similar to bile acids, they may 
be markers of liver function or indicate disruption of bile metabolism and transport as a result of cART 
intervention.    
Concentrations of a number of conjugated androgens, major urinary metabolites of testosterone, 
were reduced in the cART- exposed groups. Reduced plasma concentrations of pregnenolone, androsterone 
and dehydroepiandrosterone sulphates have been reported in patients on cART.22 It has been suggested that 
type 1 interferons, which are markers of innate immune activation, may downregulate sterol metabolism 
during anti-viral responses.33 However, it was observed that plasma levels of free and total testosterone were 
not significantly different between sample groups (Table 1), which suggests that other mechanisms, such as 
inhibition of androgen transport in the kidney epithelium, may be responsible for decreased levels of 
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androgens in the urine of cART-exposed groups. In addition, levels of SHBG, an important carrier protein for 
sex steroids, were elevated in both groups on cART, which may have resulted in increased binding of free 
androgens in plasma and less availability for metabolism and conjugation. 
Another important finding in our study was the identification of the nucleoside 5-deoxy-
5(methylthio)adenosine which was decreased in the urine of cART-treated HIV-positive patients. This 
metabolite has previously been detected at elevated levels in the urine of immunocompromised children.34,35 
It is thought to regulate cell apoptosis through the inhibition of protein carboxymethyltransferase which can 
modulate cell signalling and protein expression via protein methylation. 36,37  This potential role in apoptosis 
may be relevant in HIV disease which is a major cause of CD4 cell loss. 38,39 Furthermore, 5-deoxy-
5(methylthio)adenosine is involved in the activation of lymphocytes and thus may also be elevated as part of 
the immune response to HIV infection. 36 The possible role of 5-deoxy-5(methylthio)adenosine in HIV disease 
requires further investigation.  
Concentrations of a C17 hydroxysphinganine type of lipid were reduced in both HIV-positive groups 
on cART . To our knowledge, this is the first time this metabolite structure has been detected in human 
biofluids. However, a C17 sphinganine has been detected in human plasma as a biomarker of kidney cancer. 
40 The role of sphingolipid bases in HIV infection is currently unknown, but sphingolipids and their metabolites 
can initiate cellular apoptosis41, regulate HIV viral entry into cells42,43 and are associated with age-related 
changes in cholesterol/low density lipoprotein levels.44 Concentrations of a tetrapeptide increased in patients 
on atazanavir, possibly as a result of TDF and reduced proximal tubular function and reduced re-uptake of 
low molecular weight proteins.45,46 The effects of PI intervention on urinary protein and peptide profiles 
require further investigation. 
To conclude, this first study using trace metabolomic analyses of urine from an HIV cohort has 
revealed a number of metabolite disruptions in the urine of cART-exposed patients which need to be further 
investigated to determine their association with the side-effects of pharmaceutical intervention. However, 
this study has some limitations. As all the patients were male and white, these results cannot be extrapolated 
to other groups of HIV-positive patients, including HIV-positive women and those of non-white ethnicity. 
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Additionally, due to the cross-sectional nature of the study, direct causality with pharmaceutical intervention 
cannot be inferred. Future studies using larger sample sizes and comparing blood and plasma metabolomic 
profiles in longitudinal cohorts prior to, and during, pharmaceutical intervention will aid understanding of 
cART-related toxicity in patients. 
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Table 1: Blood and urine biochemistry of samples of study groups. 
  HIV-
negative 
(n=13) 
HIV-positive,  
cART-naïve 
(n=26) 
cART including 
atazanavir 
(n=20) 
cART including 
darunavir 
(n=30) 
Age 34±8 37±10 46±6.7(0.001,0.006) 48±7.5(0.0002,0.001) 
CD4 count at sampling(cells /µL) na 463(216-886) 593(114-1087) 540(105-1010) 
Nadir CD4 count (cells/µL) na 328(73-639) 245(4-680)na,0.01 242(30-385)na,0.001 
cART status na naïve On cART On cART 
Viral load (RNA copies/mL plasma) na 5942(40-212917)(0.0001) <40  <40 
Urine osmolality (mOsm) 735±241 644±281 700±178 577±259 
Urine creatinine (µmol/L) 14.4±8.9 13±7.7 13±4.7 12±8 
uPCR (mg/mMol) 6.7±1.2 10±4.6 14.5±8.30.002/0.1 14±7.00.0004/0.04 
uACR (mg/mMol) nd 0.9±0.7 1.0±0.9 1.5±1.9 
uAPR (ratio) nd 0.90±0.06 0.83±0.08 0.94±0.08 
ALP (IU/L) 59.4±17.1 68.7±19.6 95.5±25.20.0003/0.002 73.5±18.9 
ALT (IU/L) 26.2±18.2 24.5±12.2 32.4±21.7 33.21±73 
Plasma bilirubin (µmol/L) 12.4±3.1 7.9±2.7 32.5±15.40.0001/0.0001 7.4±2.9 
Cholesterol (mMol/L) 4.4±0.7 4.3±1.2 5.1±1.1 5.1±0.80.055/0.05 
HDL (mMol/L) 1.4±3 1.2±0.3 1.1±0.3 1.1±0.3 
Triglycerides (mMol/L) 0.96±0.7 1.38±0.6 1.65±0.6 1.91±0.870.009/0.02 
Free testosterone (pMol/L) 462±125 442±140 401±133 369±117 
Total testosterone (nMol/L) 21.7±8.3 22.3±9.6 24.1±9.6 23.2±9.5 
SHBG (nMol/L) 29.5±13.4 36.8±16.0 49.0±17.30.006/0.08 
 
52.2±23.50.005/0.07 
Study groups were 100% white males.  uPCR= urinary protein creatinine ratio, uACR= urinary albumin 
creatinine ratio,  uAPR= urinary albumin protein ratio, ALP= alkaline phosphatase, ALT= alanine transaminase. 
Values are mean (SD) with the exception of CD4 count and viral load which are reported as the median with 
the range in parenthesis.  Values in bold are significantly increased compared to HIV negative or the cART 
naïve group.  P-values for comparison with HIV negative/cART naïve groups are given in superscript. na= not 
applicable.  nd=not determined. Limit of detection of viral load was 40 RNA copies/mL plasma. 
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Table 2: The identity of cART pharmaceutical metabolites identified in urine extracts 
Metabolite Metabolite  
identity/transformation 
Retention 
time 
Experimental 
mass 
Theoretical
mass 
Formula 
Ritonavir Parent compound 24.09 721.3186 721.3191 C37H48N6O5S2  
Ritonavir M1 Hydroxylation 17.96 737.3163 737.3155 C37H48N6O6S2 
Ritonavir M2 Deacylation 17.28 580.3333 580.3321 C32H45N5O3S 
Darunavir Parent compound 18.41 548.2439 548.2430 C27H37N3O7S  
Darunavir M1  Carbamate hydrolysis 12.00 392.2014 392.2008 C20H29N3O3S  
Darunavir M2 Carbamate hydrolysis 
and hydroxylation 
10.09 408.1971 408.1957 C20H29N3O4S  
Darunavir M3 Glucuronide of M2   9.67 584.2279 584.2278 C26H37N3O10S  
Darunavir M4 Glucuronide of parent 14.11 722.2585* 722.2595* C33H45N3O13S 
Atazanavir Parent compound 19.43 705.3964 705.3976 C38H52N6O7  
Atazanavir M1 Deacylation 14.49 538.3255 538.3241 C26H43N5O7 
Atazanavir M2 Carbamate hydrolysis 12.59 647.3929 647.3921 C36H50N6O5 
Atazanavir M3 Carbamate hydrolysis 13.06 647.3912 647.3921 C36H50N6O5 
Atazanavir M4 Hydroxylation 15.41 721.3910 721.3925 C38H52N6O8 
Atazanavir M5 Keto metabolite 21.18 719.3770 719.3768 C38H50N6O8 
Tenofovir Parent compound   5.27 288.0884 288.0862 C9H14N5O4P 
Emtricitabine Parent compound   5.16 248.0522 248.0505 C8H10FN3O3S 
*Refers to m/z of [M-H]- ion, all other ions reported are [M+H]+.  
Details of fragmentation data to confirm structural identity are given in Supplementary Table S2 
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Table 3: Identification of metabolite markers of cART exposure. 
Measured 
mass m/z 
Ion 
[M+H]+ 
or 
[M-H]- 
Formula Identity Confounder Effect of 
confounder   
aR,  P-value 
Effect of cART 
treatment  
 aR,  P-value 
Effect of cART regimen 
 P-value after Bonferroni correction b(fold change from estimated 
marginal means) 
Metabolites decreased in urine of cART-exposed groups   Atazanavir vs. 
HIV-negative 
Atazanavir vs. 
cART-naïve  
Darunavir vs. 
HIV-negative 
Darunavir vs. 
cART-naïve  
247.1662 M+H C11H22N2O4 unknown Age 
uPCR 
0.08   0.4 
0.04   0.6 
0.53  4x10-6 
0.52  8x10-6 
0.1 
0.4 
0.006   (-1.2) 
0.01     (-1.2) 
0.001   (-1.3) 
0.005   (-1.3) 
2x10-6 (-1.3) 
3x10-6 (-1.3) 
298.0978 M+H C11H15N5O3S 5-deoxy-5(methylthio) 
adenosinec 
Age 
uPCR 
0.06  0.5 
0.23  0.02 
0.46  1x10-4 
0.41  0.001 
0.1 
1.0 
2x10-4   (-2.7) 
0.002    (-2.1) 
0.5 
1.0 
0.001 (-2.1) 
0.007 (-1.8) 
304.2853 M+H C17H37NO3 C17-hydroxy 
sphinganine like 
Age 
uPCR 
0.03  0.1 
0.15  0.8 
0.61 1x10-8 
0.62 1x10-8 
1.0 
1.0 
3x10-6   (-2.8) 
1x10-5   (-2.5) 
1.0 
1.0 
4x10-8 (-3.5) 
5x10-8 (-3.1) 
407.2800 M-H C24H40O5 Cholic acidc Age 
uPCR 
0.17  0.1 
0.01  0.8 
0.41  0.001 
0.36  0.007 
1.0 
1.0 
0.006   (-2.3) 
0.03     (-2.3) 
1.0 
0.8 
0.002  (-2.4) 
0.009  (-2.4) 
583.3118 M-H C30H48O11 Cholic acid glucuronide Age 
uPCR 
0.08  0.4 
0.04  0.6 
0.66  2x10-8 
0.69  7x10-12 
0.02     (-3.4) 
0.01     (-3.6) 
3x10-9  (-5.5) 
7x10-10  (-5.6) 
0.02     (-3.0) 
0.01     (-5.6) 
1x10-9  (-4.9)  
5x10-11 (-5.3) 
464.3011 M-H C26H43NO6 Glycocholic acidc Age 
uPCR 
0.09  0.3 
0.14  0.1 
0.67  5x10-11 
0.70  2x10-12 
0.0002 (-30) 
8x10-4    (-59) 
4x10-10  (-41) 
1x10-10  (-79) 
0.001   (-6.6) 
0.0003 (-9.7) 
1x10-9   (-9.2) 
1x10-10 (-9.2) 
464.3013 M-H C26H43NO6 Glycocholic acid like Age 
uPCR 
0.01 0.8 
0.14  0.1 
0.58  2x10-7 
0.63  2x10-9 
0.001   (-2.0) 
0.001   (-2.2) 
5x10-5    (-2.0) 
4x10-6    (-2.1) 
9x10-5  (-2.2) 
6x10-6  (-2.5) 
9x10-7   (-2.2) 
3x10-8   (-2.4) 
629.3537 M-H C32H54O12 Norcholestanehexol 
glucuronide 
Age 
uPCR 
0.01 0.09 
0.20  0.06 
0.80  3x10-18  
0.82  1x10-19 
3x10-9   (-1.7) 
2x10-9   (-1.7) 
6x10-15  (-1.8) 
2x10-15  (-1.8) 
3x10-10 (-1.7) 
1x10-10 (-1.7) 
1x10-16 (-1.8) 
1x10-17 (-1.8) 
367.1581 M-H C19H28O5S Testosterone sulfatec Age 
uPCR 
0.08  0.4 
0.03  0.8 
0.32  0.03 
0.36  0.008 
0.03     (-1.2) 
0.01     (-1.3) 
0.1 
0.08 
0.09 
0.03    (-1.3) 
0.4 
0.1 
369.1735 M-H C19H30O5S Dihydrotestosterone 
sulfatec 
Age 
uPCR 
0.01  0.9 
0.23  0.03 
0.45   0.0002 
0.55  2x10-6  
0.03     (-1.3) 
0.001   (-1.4) 
0.0002 (-1.3) 
6x10-6    (-1.4) 
0.2 
0.009  (-1.3) 
0.005   (-1.3) 
0.0001 (-1.3) 
369.1735 M-H C19H30O5S Unidentified androgen 
sulfate 
Age 
uPCR 
0.02  0.8 
0.01  0.9 
0.35  0.01 
0.35  0.01 
0.03     (-1.7) 
0.03    (-1.6) 
0.02     (-1.6) 
0.02     (-1.5) 
0.2 
0.2 
0.3 
0.2 
479.2283 M-H C25H36O9 Oxo-androsterone 
glucuronide 
Age 
uPCR 
0.06  0.5 
0.12  0.5 
0.44  0.0003 
0.47  0.0001 
0.02     (-1.6) 
0.01     (-1.7) 
0.0001 (-1.8) 
7x10-4    (-1.8) 
0.5 
0.3 
0.01     (-1.4) 
0.009   (-1.4) 
Metabolites increased in urine of cART-exposed groups 
539.2694 M-H C21H34N10O7 Tetrapeptide 
 (Gln/Arg/His/Thr) 
Age 
uPCR 
0.10  0.3 
0.03  0.7 
0.30  0.05 
0.34  0.01 
0.1 
0.09 
0.05   (2.2) 
0.02   (2.2) 
0.9 
0.4 
0.4 
0.1 
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Linear regression modelling was used to adjust for the confounding effects of age and urine protein/creatinine ratio on metabolite concentration.  aR=partial regression 
coefficient.  bValues in parenthesis are the fold change in metabolite intensity from estimated marginal means adjusted for the covariate.  cidentity of metabolite confirmed 
with an authentic standard and other compounds identified from exact mass and fragmentation data. A negative fold change is where the metabolite intensity is reduced 
in cART recipients relative to cART naive patients. The mean (SD) of metabolite intensities and their mass spectra data are given in Supplementary Table S3. 
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Figure 1: PCA scores plot analysis of the effect on the urinary metabolome of HIV and cART status (+nESI 
mode).  
cART-exposed groups received the NRTIs tenofovir disoproxil fumerate and emtricitabine, and the ritonavir 
protease inhibitor as well as either atazanavir or darunavir (labelled respectively). QC represent quality 
control samples (n=8). No discrimination was detected between the HIV-negative and HIV-positive cART 
naïve patients. However, both groups on cART discriminated from the cARTnaïve and HIV negative patients 
on the first component and cART groups clustered separately from each other on the second component.   
  
Quality control samples 
HIV negative 
HIV positive cART naïve 
HIV-positive on cART including atazanavir 
HIV-positive on cART including darunavir 
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Figure 2: OPLS-DA S-plot analysis of metabolite profiles in urine samples of patients on cART containing 
darunavir compared to cART-naive patients.  
Samples were analysed in +nESI mode. Each dot represents a spectral signal corresponding to retention 
time/m/z ion of a metabolite. Signals in the bottom left corner of the plot decreased in the cART-exposed 
when compared to the cART-naïve group. Signals in the top right corner increased in the cART group and 
were associated with ions corresponding to cART pharmaceuticals and their metabolites (see Table 2 and 
Supplementary Table S2 for cART metabolite identities). 
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